Melissa Vansickel
Medical · Lone Tree, CONPI 1568559250
Payments from drug & device makers
Across 444 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$989
- AbbVie$425
- Amneal Pharmaceuticals LLC$402
- AstraZeneca$392
- Mannkind Corporation$389
- plus $4K from 34 others
What the payments were for
- Food & beverage$7,58899%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 60 | $1,013 |
| Novo Nordisk | 119 | $989 |
| AbbVie | 23 | $425 |
| Amneal Pharmaceuticals LLC | 25 | $402 |
| AstraZeneca(2 entities) | 18 | $392 |
| Mannkind Corporation | 28 | $389 |
| Boehringer Ingelheim | 13 | $333 |
| Medtronic | 10 | $319 |
| Radius Health, Inc. | 14 | $295 |
| Sanofi-aventis U.S. LLC | 15 | $294 |
| Amphastar Pharmaceuticals, Inc. | 6 | $281 |
| Antares Pharma, Inc. | 11 | $231 |
| Bayer | 10 | $208 |
| Abbott | 8 | $182 |
| Tandem Diabetes Care, Inc. | 9 | $171 |
| IBSA Pharma Inc. | 8 | $160 |
| Cequr Corporation | 3 | $153 |
| Dexcom, Inc. | 6 | $133 |
| Amgen | 7 | $128 |
| Pfizer | 5 | $103 |
| Neurocrine Biosciences, Inc. | 3 | $103 |
| Boston Scientific | 2 | $96 |
| Recordati_rare_diseases_inc. | 4 | $94 |
| Insulet Corporation | 5 | $92 |
| Currax Pharmaceuticals LLC | 6 | $91 |
| Ultragenyx Pharmaceutical Inc. | 4 | $76 |
| Ascendis Pharma Endocrinology Inc | 3 | $60 |
| BETA Bionics, Inc. | 4 | $58 |
| Astellas Pharma US Inc | 2 | $56 |
| Amryt Pharma Holdings Ltd | 2 | $55 |
| Lifescan, Inc. | 2 | $44 |
| Zealand Pharma US, Inc. | 1 | $31 |
| Halozyme Inc | 1 | $30 |
| Sequel Med Tech, LLC | 1 | $25 |
| Corcept Therapeutics | 1 | $23 |
| Novartis | 1 | $22 |
| GRT US Holding, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$106
How this compares
$7,634 in reported general payments places this provider in the 90th percentile of 766 medical providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $246,014 |
| MounjaroTirzepatide | 159 | $231,920 |
| JardianceEmpagliflozin | 102 | $130,835 |
| TrulicityDulaglutide | 25 | $52,563 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $49,161 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $44,138 |
| FarxigaDapagliflozin Propanediol | 22 | $33,022 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $31,138 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $30,194 |
| JanuviaSitagliptin Phosphate | 16 | $27,828 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $25,433 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $24,216 |
| InvokanaCanagliflozin | 15 | $22,457 |
| Repatha SureclickEvolocumab | 15 | $18,158 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $14,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,013 | $299,801244 claims |
| Novo NordiskOzempic, Novolog | $989 | $255,527205 claims |
| Boehringer IngelheimJardiance | $333 | $130,835102 claims |
| AstraZenecaFarxiga | $392 | $33,02222 claims |
| AbbVieSynthroid | $425 | $12,066109 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $402 | $5,556357 claims |
| Sanofi-aventis U.S. LLCLantus | $294 | $1,77516 claims |
| PfizerLevoxyl | $103 | $1,08718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 766 medical providers in Colorado.
Other medical in Lone Tree
- Virginia HindsLone Tree$41K
- Jessica RamirezLone Tree$10K
- Susan GieskeLone Tree$9K
- Christen KutzColorado Springs$2.4M
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.